<DOC>
	<DOCNO>NCT02111577</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/PCa add onto Standard Care Chemotherapy improve survival time patient Metastatic Castration Resistant Prostate Cancer .</brief_summary>
	<brief_title>Phase III Study DCVAC Added Standard Chemotherapy Men With Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Male 18 year old Histologically cytologically confirm prostate adenocarcinoma Presence skeletal , and/or softtissue/visceral/nodal metastasis Disease progression despite Androgen Deprivation Therapy Maintenance castrate condition Life expectancy least 6 month base InvestigatorÂ´s judgment . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 At least 4 week surgery radiotherapy A minimum 28 day beyond initiation bisphosphonate denosumab therapy Recovery primary local surgical treatment , radiotherapy orchiectomy Confirmed brain and/or leptomeningeal metastasis Current symptomatic cord compression require surgery radiation therapy Prior chemotherapy prostate cancer Subjects indicate chemotherapy treatment first line Standard Care chemotherapy ( docetaxel prednisone ) Systemic corticosteroid dos great 40mg hydrocortisone daily equivalent reason treatment prostate cancer ( PCa ) within previous 6 month Systemic immunosuppressive therapy reason Treatment immunotherapy PCa within previous 6 month prior randomization Clinically significant cardiovascular disease Active autoimmune disease require treatment Uncontrolled comorbidities Participation clinical trial use experimental therapy within last 4 week prior randomization Participation clinical trial use immunological experimental therapy ( e.g . monoclonal antibody , cytokine active cellular immunotherapy ) within last 6 month prior randomization</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castrate Resistant</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>